Aerofylline is a new generation methylxanthine bronchodilator.

The product is used for the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma. Aerofylline is almost devoid of adverse effects which may account for its unique safety profile among methylxanthine products.

Pharmacotherapeutic group: preparations used for the treatment of bronchoobstructive diseases. Methylxanthine group.

Composition: 1 tablet contains Doxofylline 400 mg.

Packaging description: 20 tablets per pack, 2 blister per pack.

Registration certificate: № UA/4391/01/01